Validation and analysis of a mathematical model of a replication-competent oncolytic virus for cancer treatment: Implications for virus design and delivery

Cancer Research

Volumn 63, Issue 6, 2003, Pages 1317-1324

  Wein, Lawrence M ^a   Wu, Joseph T ^b   Kirn, David H ^c,d  

^a MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^b MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^c UNIVERSITY OF OXFORD   (United Kingdom)

^d Kirn Oncology Consulting   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ONCOLYTIC VIRUS;

ACCURACY; ANTINEOPLASTIC ACTIVITY; ARTICLE; IMMUNE RESPONSE; MATHEMATICAL MODEL; PRIORITY JOURNAL; THREE DIMENSIONAL IMAGING; TUMOR VASCULARIZATION; VALIDATION PROCESS; VIRAL GENE THERAPY; VIRUS REPLICATION;

MODELS, BIOLOGICAL; NEOPLASMS; REPRODUCIBILITY OF RESULTS; SPHEROIDS, CELLULAR; VIRAL PHYSIOLOGY; VIRUS REPLICATION;

EID: 0037444281     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. McCormick, F. Cancer gene therapy: fringe or cutting edge? Nat. Rev. Cancer, 1: 130-141, 2001.
2. Kirn, D., Martuza, R. L., and Zwiebel, J. Replication-selective virotherapy for cancer: biological principles, risk management and future directions. Nat. Med., 7: 781-787, 2001.
3. Bischoff, J. R., Kirn, D. H., Williams, A., Heise, C., Horn, S., Muna, M., Ng, L., Nye, J. A., Sampson-Johannes, A., Fattaey, A., and McCormick, F. An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science (Wash. DC), 274: 373-376, 1996.
4. Heise, C., Sampson-Johannes, A., Williams, A., McCormick, F., Von Hoff, D. D., and Kirn, D. H. ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents. Nat. Med., 3: 639-645, 1997.
5. Yu, D., Chen, Y., Dilley, J., Li, Y., Embry, M., Zhang, H., Amin, P., Oh, J., and Henderson, D. Antitumor synergy of CN787, a prostate cancer-specific adenovirus, and paclitaxel and docetaxel. Cancer Res., 61: 517-525, 2001.
6. Ganly, I., Kirn, D., Eckhardt, G., Rodriguez, G. I., Soutar, D. S., Otto, R., Robertson, A. G., Park, O., Gulley, M. L., Heise, C., Von Hoff, D. D., Kaye, S. B., and Eckhardt, S. G. A Phase I study of ONYX-015, an E1B-attenuated adenovirus, administered intratumorally to patients with recurrent head and neck cancer. Clin. Cancer Res., 6: 798-806, 2000.
7. Khuri, F. R., Nemunaitis, J., Ganly, I., Arseneau, J., Tannock, I. F., Romel, L., Gore, M., Ironside, J., MacDougall, R. H., Heise, C., Randley, B., Gillenwater, A. M., Bruse, P., Kaye, S. B., Hong, W. K., and Kirn, D. H. A controlled trial of ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer. Nat. Med., 6: 879-885, 2000.
8. Mineta, T., Rabkin, S., Yazaki, T., Hunter, W., and Martuza, R. Attenuated multimutated herpes simplex virus-1 for the treatment of malignant gliomas. Nat. Med., 1: 938-943, 1995.
9. Rodriguez, R., Schuur, E. R., Lim, H. Y., Henderson, G. A., Simons, J. W., and Henderson, D. R. Prostate attenuated replication competent adenovirus (ARCA) CN706: a selective cytotoxic for prostate-specific antigen-positive prostate cancer cells. Cancer Res., 57: 2559-2563, 1997.
10. Coffey, M. C., Strong, J. E., Forsyth, P. A., and Lee, P. W. K. Reovirus therapy of tumors with activated Ras pathways. Science (Wash. DC), 282: 1332-1334, 1998.
11. Nemunaitis, J., Ganly, I., Khuri, F., Arseneau, J., Kuhn, J., McCarty, T., Landers, S., Maples, P., Romel, L., Randley, B., Reid, T., Kaye, S., and Kirn, D. Selective replication and oncolysis in p53 mutant tumors with ONYX-015, an E1B-55kD gene-deleted adenovirus, in patients with advanced head and neck cancer: a Phase II trial. Cancer Res., 60: 6359-6366, 2000.
12. Kirn, D. Clinical research results with dl1520 (Onyx-015), a replication-selective adenovirus for the treatment of cancer: what have we learned? Gene Ther., 8: 89-98, 2001.
13. Rampling, R., Cruickchank, G., Papanastassiou, V., Nicoll, J., Hadley, D., Brennan, D., Petty, R., Maclean, A., Harland, J., McKie, E., Mabbs, R., and Brown, M. Toxicity evaluation of replication-competent herpes simplex virus (ICP 34.5 null mutant 1716) in patients with recurrent malignant glioma. Gene Ther., 7: 1-4, 2000.
14. Markert, J., Medlock, M., Rabkin, S., Gillespie, G., Todo, T., Hunter, W., Palmer, C., Feigenbaum, F., Tornatore, C., Tufaro, F., and Martuza, R. Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a Phase I trial. Gene Ther., 7: 867-874, 2000.
15. McFadden, R., and Kwok, C. S. Mathematical model of simultaneous diffusion and binding of antitumor antibodies in multicellular human tumor spheroids. Cancer Res., 48: 4032-4037, 1988.
16. van Osdol, W., Fujimori, K., and Weinstein, J. N. An analysis of monoclonal antibody distribution in microscopic tumor nodules: consequences of a "binding site barrier." Cancer Res., 51: 4776-4784, 1991.
17. Baxter, L. T., and Jain, R. K. Transport of fluid and macromolecules in tumors. I. Role of interstitial pressure and convection. Microvasc. Res., 37: 77-104, 1989.
18. Baxter, L. T., and Jain, R. K. Transport of fluid and macromolecules in tumors. II. Role of heterogeneous perfusion and lymphatics. Microvasc. Res., 40: 246-263, 1990.
19. Baxter, L. T., and Jain. R. K. Transport of fluid and macromolecules in tumors. III. Role of binding and metabolism. Microvasc. Res., 41: 5-23, 1991.
20. Swabb, E. A., Wei, J., and Gullino, P. M. Diffusion and convection in normal and neoplastic tissues. Cancer Res., 34: 2814-2822, 1974.
21. Jain, R. Barriers to drug delivery in solid tumors. Sci. Am., 271: 58-65, 1994.
22. Nemunaitis, J., Cunningham, C., Buchanan, A., Blackburn, A., Edelman, G., Maples, P., Netto, G., Tong, A., Randley, B., Olson, S., and Kirn, D. Intravenous infusion of a replication-selective adenovirus (ONYX-015) in cancer patients: safety, feasibility and biological activity. Gene Ther., 8: 746-759, 2001.
23. Wu, J. T., Byrne, H. M., Kirn, D. H., and Wein, L. M. Modeling and analysis of a virus that replicates selectively in tumor cells. Bull. Math. Biol., 63: 731-768, 2001.
24. Wu, J. T., Kirn, D. H., and Wein, L. M. Analysis of a three-way race between tumor growth, a replication-competent virus and an immune response. Bulletin Math Biol., in press, 2003.
25. Reid, T., Galanis, E., Abbruzzese, J., Sze, D., Andrews, J., Romel, L., Hatfield, M., Rubin, J., and Kirn, D. Intra-arterial administration of a replication-selective adenovirus (dl1520) in patients with colorectal carcinoma metastatic to the liver: a Phase I trial. Gene Ther., 8: 1618-26, 2001.
26. Heise, C., Williams, A., Olesch, J., and Kirn, D. H. Efficacy of a replication-competent adenovirus (ONYX-015) is associated with intratumoral distribution. Cancer Gene Ther., 6: 499-504, 1999.
27. Yoon, S. S., Carroll, N. M., Chiocca, E. A., and Tanabe, K. K. Cancer gene therapy using a replication-competent herpes simplex virus type I vector. Ann. Surg., 228: 366-374, 1998.
28. Heise, C. C., Williams, A. M., Xue, S., Propst, M. and Kirn, D. H. Intravenous administration of ONYX-015, a selectively replicating adenovirus, induces antitumoral efficacy. Cancer Res., 59: 2623-2628, 1999.
29. O'Donoghue, J. A., Bardies, M., and Wheldon, T. E. Relationships between tumor size and curability for uniformly targeted therapy with β-emitting radionuclides. J. Nucl. Med., 36: 1902-1909, 1995.
30. Fowler, J. F. The phantom of tumor treatment - continually rapid proliferation unmasked. Radiother. Oncol., 22: 156-158, 1991.
31. Boucher, Y., Salehi, H., Witwer, B., Harsh, IV, G. R., and Jain, R. K. Interstitial fluid pressure in intracranial tumours in patients and in rodents. Br. J. Cancer (Phil.), 75: 829-836, 1997.
32. Heise, C., Hermiston, T., Johnson, L., Brooks, G., Sampson-Johannes, A., Williams, A., Hawkins, L., and Kirn, D. An adenovirus EIA mutant that demonstrates potent and selective systemic antitumoral efficacy. Nat. Med., 6: 1134-1139, 2000.
33. Doronin, K., Toth, K., Kuppuswamy, M., Ward, P., Tollefson, A., and Wold, W. Tumor-specific, replication-competent adenovirus vectors overexpressing the adenovirus death protein. J. Virol., 74: 6147-6155, 2000.
34. Hawkins, L. K., and Hermiston, T. Gene delivery from the E3 region of replicating human adenovirus: evaluation of the ADP region. Gene Ther., 15: 1142-1148, 2001.
35. Rogulski, K. R., Freytag, S. O., Zhang, K., Gilbert, J. D., Paielli, D. L., Kirn, J. H., Heise, C. C., and Kirn, D. H. In vivo antitumor activity of ONYX-015 is influenced by p53 status and is augmented by radiotherapy. Cancer Res., 60: 1193-1196, 2000.
36. Wodarz, D. Viruses as antitumor weapons: defining conditions for tumor remission. Cancer Res., 61: 3501-3507, 2001.
37. van den Bosch, F., Metz, J. A. J., and Kiekmann, O. The velocity of spatial population expansion. J. Math. Biol., 28: 529-565, 1990.